Toshihiko Doi

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 36

Top Topics

Locally Advanced

Tyrosine Kinase

Liver Metastases

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer chemotherapy and pharmacology

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine 13 (8) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology (2024)
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine 13 (8) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine 13 (8) (2024)
Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Makiko Ono, Tetsuya Urasaki, Akihiro Ohmoto, Tsubasa Kawanai, Takashi Hisai, Hiroki Ikezawa, Sari Shiba, Ken Ito, Taro Semba, Osamu Asano, Shunji Takahashi
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part. Cancer (2023)
Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Makiko Ono, Tetsuya Urasaki, Akihiro Ohmoto, Tsubasa Kawanai, Takashi Hisai, Hiroki Ikezawa, Sari Shiba, Ken Ito, Taro Semba, Osamu Asano, Shunji Takahashi
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part. Cancer (2023)
Toshihiko Doi, Noboru Yamamoto, Shuichi Ohkubo
Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors. Future oncology (London, England) (2023)
Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Makiko Ono, Tetsuya Urasaki, Akihiro Ohmoto, Tsubasa Kawanai, Takashi Hisai, Hiroki Ikezawa, Sari Shiba, Ken Ito, Taro Semba, Osamu Asano, Shunji Takahashi
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part. Cancer (2023)
Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Makiko Ono, Tetsuya Urasaki, Akihiro Ohmoto, Tsubasa Kawanai, Takashi Hisai, Hiroki Ikezawa, Sari Shiba, Ken Ito, Taro Semba, Osamu Asano, Shunji Takahashi
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part. Cancer (2023)
Toshihiko Doi, Kohei Shitara, Takashi Kojima, Yasutoshi Kuboki, Nobuaki Matsubara, Hideaki Bando, Kiyotaka Yoh, Yoichi Naito, Hiroshi Hirai, Yukinori Kurokawa, Terufumi Kato, Chigusa Morizane
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer science (2022)
Hiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, Syohei Koyama, Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Masako Asayama, Takako Yoshii, Hideaki Bando, Daisuke Kotani, Yoshiaki Nakamura, Yasutoshi Kuboki, Saori Mishima, Masashi Wakabayashi, Takeshi Kuwata, Masahiro Goto, Kazuhide Higuchi, Takayuki Yoshino, Toshihiko Doi, Hiroyoshi Nishikawa, Kohei Shitara
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Filip Janku, Sae-Won Han, Toshihiko Doi, Alessio Amatu, Jaffer A Ajani, Yasutoshi Kuboki, Alex Cortez, Susan E Cellitti, Ping C Mahling, Kulandayan Subramanian, Heidi A Schoenfeld, Sarah M Choi, Lori A Iaconis, Lang Ho Lee, Marc R Pelletier, Glenn Dranoff, Vasileios Askoxylakis, Salvatore Siena
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer immunology research 10 (12) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Toshihiko Doi, Yasutoshi Kuboki, Yoichi Naito, Masahiro Ishida, Tetsuya Tanaka, Yoshito Takeuchi
A phase 1 trial of xentuzumab, an IGF-neutralizing antibody, in Japanese patients with advanced solid tumors. Cancer science (2021)
Matthew D Hellmann, Nicoletta Bivi, Boris Calderón, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M Szpurka, Victoria Copeland, F Stephen Hodi, Sylvie Rottey, Philippe Aftimos, Yongzhe Piao, Leena Gandhi, Violeta Regnier Galvao, Ching Ching Leow, Toshihiko Doi
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Hiroyasu Aoki, Satoshi Ueha, Shigeyuki Shichino, Haru Ogiwara, Kohei Shitara, Manami Shimomura, Toshihiro Suzuki, Tetsuya Nakatsura, Makiko Yamashita, Shigehisa Kitano, Sakiko Kuroda, Masashi Wakabayashi, Makoto Kurachi, Satoru Ito, Toshihiko Doi, Kouji Matsushima
Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. Cancer immunology research 9 (6) (2021)
Curigliano Giuseppe, André B P van Kuilenburg, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M Forde, John Sarantopoulos, Philippe L Bedard, Chia-Chi Lin, F Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A Sabatos-Peyton, Tyler A Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (13) (2021)
Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, Hideaki Bando, Hisateru Yasui, Taito Esaki, Tetsuji Terazawa, Taroh Satoh, Eiji Shinozaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Hiroki Hara, Eiji Oki, Nobuhisa Matsuhashi, Takashi Ohta, Takeshi Kato, Koushiro Ohtsubo, Takeshi Kawakami, Naohiro Okano, Yoshiyuki Yamamoto, Takanobu Yamada, Akihito Tsuji, Justin I Odegaard, Hiroya Taniguchi, Toshihiko Doi, Satoshi Fujii, Takayuki Yoshino
Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (20) (2021)
Kenji Iida, Amr H Abdelhamid Ahmed, Akiko Kawano Nagatsuma, Tomoko Shibutani, Satoru Yasuda, Michiko Kitamura, Chiharu Hattori, Manabu Abe, Jun Hasegawa, Takuma Iguchi, Tsuyoshi Karibe, Takashi Nakada, Koichiro Inaki, Reiko Kamei, Yuki Abe, Taisei Nomura, Jessica L Andersen, Sandro Santagata, Matthew L Hemming, Suzanne George, Toshihiko Doi, Atsushi Ochiai, George D Demetri, Toshinori Agatsuma
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer discovery 11 (6) (2021)
Adi Diab, Omid Hamid, John A Thompson, Willeke Ros, Ferry A L M Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Kai H Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B El-Khoueiry
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Takashi Kojima, Manish A Shah, Kei Muro, Eric Francois, Antoine Adenis, Chih-Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung-Bae Kim, Se-Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter Enzinger, Shu-Kui Qin, Paula Ferreira, Jia Chen, Gustavo C Girotto, Christelle De La Fouchardière, Helene Senellart, Raed Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, S Peter Kang, Jean-Philippe Metges, null null
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (35) (2020)
Toshihiko Doi, Narikazu Boku, Yusuke Onozawa, Keishiro Takahashi, Osamu Kawaguchi, Atsushi Ohtsu
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies. Investigational new drugs 38 (5) (2020)
Yohei Kubota, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Kentaro Sawada, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Genichiro Ishii, Takeshi Kuwata, Kohei Shitara
The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (14) (2020)
Toshihiko Doi, Masaomi Tajimi, Joji Mori, Hiroya Asou, Koichi Inoue, Karim A Benhadji, Yoichi Naito
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors. Investigational new drugs 39 (2) (2020)
Yoon-Koo Kang, Yung-Jue Bang, Shunsuke Kondo, Hyun Cheol Chung, Kei Muro, Isabelle Dussault, Christoph Helwig, Motonobu Osada, Toshihiko Doi
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (13) (2020)
Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, Toshio Shimizu, Kan Yonemori, Nobuaki Matsubara, Izumi Ohno, Takahiro Kogawa, Yoichi Naito, Lance Leopold, Mihaela Munteanu, Naoyoshi Yatsuzuka, Shi Rong Han, Ayman Samkari, Noboru Yamamoto
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). Investigational new drugs 39 (1) (2020)
Toshihiko Doi, Nobuaki Matsubara, Akira Kawai, Norifumi Naka, Shunji Takahashi, Hiroji Uemura, Noboru Yamamoto
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors. Investigational new drugs 38 (4) (2019)
Toshihiko Doi, Yutaka Fujiwara, Nobuaki Matsubara, Junichi Tomomatsu, Satoru Iwasa, Akari Tanaka, Chihiro Endo-Tsukude, Shintaro Nakagawa, Shunji Takahashi
Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 84 (2) (2019)
Satoru Iwasa, Noboru Yamamoto, Kohei Shitara, Kenji Tamura, Nobuaki Matsubara, Masaomi Tajimi, Aimee B Lin, Hiroya Asou, Zhihong Cai, Koichi Inoue, Yuko Shibasaki, Kanako Saito, Hiroki Takai, Toshihiko Doi
Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. Cancer science 109 (10) (2018)
Toshihiko Doi, Kiyotaka Yoh, Kohei Shitara, Hideaki Takahashi, Makoto Ueno, Satoshi Kobayashi, Manabu Morimoto, Takuji Okusaka, Hideki Ueno, Chigusa Morizane, Naohiro Okano, Fumio Nagashima, Junji Furuse
First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. Investigational new drugs 37 (3) (2018)
Kiyotaka Yoh, Toshihiko Doi, Hironobu Ohmatsu, Takashi Kojima, Hideaki Takahashi, Yoshitaka Zenke, Volker Wacheck, Sotaro Enatsu, Takashi Nakamura, Kellie Turner, Kazunori Uenaka
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies. Investigational new drugs 34 (5) (2016)